
Effects of parathyroidectomy on bone remodeling markers and vitamin D status in patients with chronic kidney disease–mineral and bone disorder
Received: 1 February 2007 Accepted: 27 June 2007
Published online: 7 August 2007
Abstract
Background/Aims Chronic renal failure (CRF) is often associated with bone disorders including chronic kidney disease–mineral and bone disorder (CKD–MBD).
Parathyroid hormone (PTH) has a relationship to bone remodeling, and so this study was undertaken to evaluate changes in bone remodeling markers after parathyroidectomy (PTX).
Methods:
Twelve adult patients, mean age 43.4 ± 12.7 years, of both genders, were evaluated, prior to and six months after PTX. Analysis of biochemical markers of bone metabolism, such as total and ionized calcium, phosphorus, 25(OH)D3, total alkaline phosphatase (TAP), bone-specific alkaline phosphatase (BAP), intact PTH, osteoprotegerin (OPG), and tartrate-resistant acid phosphatase isoform 5b (TRAP), were measured.
Results:
No changes were observed after PTX in the serum total and ionized calcium, TAP, BAP, and 25(OH)D3.
After surgery there was a significant decrease in serum phosphorus, iPTH, and TRAP (P < 0.001).
No significant change was observed in OPG; however there was a positive correlation between OPG and 25(OH)D3 before and after surgery (r = 0.774, P = 0.014; and r = 0.706, P = 0.01, respectively).
The percentage of patients with vitamin D deficiency decreased from 16.7% to 8.3%, while those with sufficient levels increased from 41.7% to 58.3%.
Conclusion:
The small number of patients in the study notwithstanding, the present study is unique because it provides information on bone metabolism and vitamin D status six months after PTX.
The removal of parathyroid glands significantly decreased bone resorption and indicated a tendency of 25(OH)D3 concentration to increase.
However, the precise role of OPG and BAP in the improvement in bone remodeling in patients with CKD–MBD requires further study.
Keywords:
Chronic renal failure - Hemodialysis - Parathyroidectomy - Chronic kidney disease–mineral and bone disorder - Osteoprotegerin - Tartrate-resistant acid phosphatase isoform 5b - Vitamin D
European Journal of Clinical Nutrition
advance online publication 8 August 2007; doi: 10.1038/sj.ejcn.1602861
Combined calcium and vitamin D supplementation is not superior to calcium supplementation alone in improving disturbed bone metabolism in patients with congestive heart failure
Objectives:
To clarify the potential role of vitamin D supplementation on bone metabolism in congestive heart failure (CHF) patients with low vitamin D status and insufficient dietary calcium intake.
Subjects/Methods:
One hundred and two ambulatory male CHF patients were recruited, of whom the majority was treated with loop diuretics. Nine patients died during follow-up.
Additional 14 participants dropped out prematurely because their health status worsened markedly.
Five patients had to be excluded due to lack of compliance.
A daily vitamin D3 supplement plus 500 mg calcium (CaD group) or a placebo plus 500 mg calcium (Ca group) was given for 9 months. Biochemical parameters of vitamin D and bone metabolism were analyzed at baseline and after 9 months.
Results:
Median 25-hydroxyvitamin D concentrations increased from 41.7 to 103.0 nmol/l (P<0.001) in the CaD group and remained constant in the Ca group, while median calcium intake increased above 1200 mg/day in both groups.
The percentage of patients with elevated parathyroid hormone levels (>60 pg/ml), as well as the serum concentration of undercarboxylated osteocalcin, an indicator of osteoporotic fracture risk and the bone resorption marker C-telopeptide fell significantly in both study groups (P<0.025–0.001).
At the end of the study period, biomarkers of bone turnover did not differ between groups.
Conclusions:
A vitamin D3 supplement of 50 g/day has no additional beneficial effects on markers of bone metabolism in CHF patients with low initial 25-hydroxyvitamin D concentrations if an adequate daily calcium intake is guaranteed.
Keywords:
vitamin D, calcium, parathyroid hormone, bone markers, supplementation
http://www.nature.com/ejcn/journal/vaop ... CD24655D16

Nee ik heb hypoparathoide en geen hyper
:kus2:
:kus2: :kus2:
:kus2:
:kus2:
:kus2:
:kus2: :kus2: :kus2:
Keer terug naar Alternatieve behandeling
Gebruikers op dit forum: Geen geregistreerde gebruikers. en 1 gast